Top 10 Naltrexone (Revia) Generic Manufacturers in Mexico
The pharmaceutical industry in Mexico has witnessed significant growth in recent years, particularly in the production of generic drugs. As of 2022, the Mexican pharmaceutical market was valued at approximately $19 billion, with generics accounting for around 80% of total prescriptions. Naltrexone, known commercially as Revia, is a critical medication used in the treatment of opioid addiction and alcohol dependence. The demand for generic versions of Naltrexone is increasing due to their cost-effectiveness and accessibility. This report highlights the top manufacturers of Naltrexone in Mexico, showcasing their production capabilities and market contributions.
1. Laboratorios Liomont, S.A. de C.V.
Laboratorios Liomont is a leading player in the Mexican pharmaceutical market, with a strong focus on generics. They produce Naltrexone under the brand name Revia, contributing significantly to the market. In 2022, Liomont had an estimated production volume of over 10 million units annually.
2. Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab is a major pharmaceutical company in Mexico, producing various medications, including Naltrexone. The company reported a revenue of approximately $750 million in 2022, with generics constituting a significant portion of their sales.
3. Laboratorios Pisa, S.A. de C.V.
Laboratorios Pisa is one of Mexico’s largest manufacturers of generic pharmaceuticals. The company has a diverse product portfolio that includes Naltrexone, with an annual production capacity estimated at 8 million units. Pisa holds a substantial market share of approximately 12% in the generic segment.
4. Sanfer, S.A. de C.V.
Sanfer is a prominent pharmaceutical company that has expanded its operations in the generic drug market. They manufacture Naltrexone as part of their commitment to providing affordable healthcare solutions. Sanfer’s market share in the generics sector is around 10%, with a production capacity of 5 million units.
5. Laboratorios Grin, S.A. de C.V.
Laboratorios Grin specializes in the development and manufacturing of generic drugs. They produce Naltrexone, contributing to the company’s overall revenue of approximately $300 million in 2022. Grin’s production facilities are capable of producing over 4 million units annually.
6. Pharmasyn, S.A. de C.V.
Pharmasyn is known for its focus on biotechnology and generic drugs, including Naltrexone. The company reported a steady growth rate of 15% in its generics division, with Naltrexone contributing to a production volume of around 3 million units.
7. Laboratorios HRA Pharma
HRA Pharma is a global player with a strong presence in Mexico’s pharmaceutical landscape. They produce Naltrexone as part of their generic offerings, and in 2022, their estimated revenue reached $500 million, with generics accounting for a significant share.
8. Fresenius Kabi Mexico, S.A. de C.V.
Fresenius Kabi is recognized for its high-quality generic drugs, including Naltrexone. The company has a robust manufacturing capability with an annual production volume of over 6 million units, catering to both domestic and international markets.
9. Grupo Farmacéutico Somar, S.A. de C.V.
Grupo Farmacéutico Somar has established itself as a trusted name in the production of generic pharmaceuticals. Naltrexone is one of their key products, contributing to a market share of approximately 5% in the generics sector, with a production capacity of 2 million units.
10. Laboratorios Farmacéuticos Liconsa, S.A. de C.V.
Liconsa is a noteworthy manufacturer that specializes in generics. Their production of Naltrexone aligns with the company’s strategic focus on addiction therapies. Liconsa’s annual production of Naltrexone is estimated at about 1.5 million units.
Insights
The market for Naltrexone generics in Mexico is poised for growth, driven by increasing awareness of addiction treatments and the rising demand for affordable healthcare solutions. The generics market is expected to reach $24 billion by 2025, with a compound annual growth rate (CAGR) of around 6%. Additionally, the ongoing emphasis on public health initiatives to combat opioid addiction is likely to bolster the demand for Naltrexone generics, providing a significant opportunity for manufacturers in this sector. As competition intensifies, companies will need to focus on quality, efficiency, and innovation to maintain their market positions.
Related Analysis: View Previous Industry Report
